Sugi Predict

Sugi Predict / Targets / NEK11

NEK11

Serine/threonine-protein kinase Nek11 · Q8NG66 · NEK11 on Sugi Atlas →

4,839 patent compounds predicted against NEK11, 4,236 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Plx-4720 Plx-4720 (SCHEMBL133733) 1.00 2/20
Vemurafenib Vemurafenib (SCHEMBL298931) 1.00 2/20
SCHEMBL298368 SCHEMBL298368 0.91 2/20
SCHEMBL298760 SCHEMBL298760 0.90 2/20
SCHEMBL298198 SCHEMBL298198 0.88 2/20
SCHEMBL293053 SCHEMBL293053 0.88 2/20
SCHEMBL298626 SCHEMBL298626 0.87 2/20
SCHEMBL299099 SCHEMBL299099 0.86 2/20
SCHEMBL298282 SCHEMBL298282 0.84 2/20
SCHEMBL298379 SCHEMBL298379 0.84 2/20
SCHEMBL855882 SCHEMBL855882 0.83 2/20
SCHEMBL298349 SCHEMBL298349 0.83 2/20
SCHEMBL299672 SCHEMBL299672 0.83 2/20
SCHEMBL293377 SCHEMBL293377 0.83 2/20
SCHEMBL298613 SCHEMBL298613 0.82 2/20
SCHEMBL294160 SCHEMBL294160 0.82 2/20
SCHEMBL294126 SCHEMBL294126 0.81 2/20
SCHEMBL414596 SCHEMBL414596 0.81 2/20
SCHEMBL297768 SCHEMBL297768 0.80 2/20
SCHEMBL298366 SCHEMBL298366 0.80 2/20

Clinical trials — most relevant to NEK11 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Acelarin First Line Randomised Pancreatic Study PHASE2/PHASE3SUSPENDED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) PHASE1/PHASE2NOT_YET_RECRUITING
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations PHASE2COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer PHASE2COMPLETED
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers PHASE1/PHASE2RECRUITING
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... PHASE2COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer PHASE2COMPLETED
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b PHASE1COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy PHASE1RECRUITING
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel PHASE1COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors PHASE1COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
The Roles of Neutrophil Elastase in Lung Cancer nanUNKNOWN
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients nanRECRUITING
Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma nanCOMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Genetics of Neonatal Encephalopathy and Related Disorders nanRECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Single-cell Sequencing and Establishment of Models in Neuroendocrine Neoplasm nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a NEK11 binder may also engage these)

ProteinNameSimilarity
Q8WNU8 — 1.000 Q8WNU8 →
Q8C0Q4 — 0.994 Q8C0Q4 →
D4A7V9 — 0.989 D4A7V9 →
P0C218 — 0.988 P0C218 →
P35761 — 0.988 P35761 →
Q8RXT4 — 0.988 Q8RXT4 →
Q8S8Y8 — 0.987 Q8S8Y8 →
EIF2AK4 eIF-2-alpha kinase GCN2 0.987 landscape →
Q6YY75 — 0.987 Q6YY75 →
O70551 — 0.987 O70551 →
Q2QMH1 — 0.987 Q2QMH1 →
Q68UT7 — 0.986 Q68UT7 →
KAT2B Histone acetyltransferase KAT2B 0.986 landscape →
Q9QZ05 — 0.986 Q9QZ05 →
Q8AYG3 — 0.986 Q8AYG3 →
Q8NG08 — 0.985 Q8NG08 →
B2GUY1 — 0.985 B2GUY1 →
Q5RD27 — 0.985 Q5RD27 →
Q9Z2R9 — 0.985 Q9Z2R9 →
E1BTE1 — 0.985 E1BTE1 →
Q2KI79 — 0.984 Q2KI79 →
SRPK1 SRSF protein kinase 1 0.984 landscape →
Q9Z1J2 — 0.984 Q9Z1J2 →
Q8RX66 — 0.984 Q8RX66 →
Q6P5G0 — 0.984 Q6P5G0 →
Q4R8E0 — 0.984 Q4R8E0 →
Q94C95 — 0.984 Q94C95 →
Q944Q0 — 0.984 Q944Q0 →
Q63562 — 0.983 Q63562 →
Q9CAV6 — 0.983 Q9CAV6 →